MedTrace Logo

Transfer Strategy in an Oocyte Donation Programme

NCT03088735 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2021-06-29

No results posted yet for this study

Summary

It has been previously shown that although the activation of the embryonic genome can begin as early as two days of initiation of the embryonic development (D2), it is expressed on day 3 (D3). Without this activation, the embryo can not continue its development. Therefore, it has been suggested that extended culture to blastocyst stage could be an option to identify and better select embryos that have been able to carry out this activation. The purpose of this study is to compare cumulative pregnancy and live birth rates following transfer of cleavage embryos or blastocysts.

Conditions

  • Oocyte Donation
  • Infertility, Female
  • Embryo Transfer

Interventions

PROCEDURE

Blastocyst-stage embryo transfer strategy

Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.

PROCEDURE

Cleavage-stage embryo transfer strategy

Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients

Sponsors & Collaborators

  • Fundacion Dexeus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-05
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03088735 on ClinicalTrials.gov